Multimedia

Drug diversion risk mitigation practices vital for health care organizations

Presented by Janice Ahlstrom, FHIMSS, CPHIMS, CCSFP, RN, BSN, Director and Kim Wylam, SPHR, President and Managing Partner, Baker Tilly Vantagen

In a recent CPA Conversations podcast with the PICPA, Baker Tilly Director, Janice Ahlstrom and Baker Tilly Vantagen President and Managing Partner, Kim Wylam, discuss drug diversion and the important role the formulation of a comprehensive risk and internal audit approach can serve to help prevent and detect drug diversion.


Listen to and/or read the podcast here

geometric ceiling
Next up

Can your IT SOX program withstand the PCAOB?